-
公开(公告)号：EP1879851A1
公开(公告)日：2008-01-23
申请号：EP06759589.2
申请日：2006-05-10
IPC分类号： C07C227/16 , C07C227/32 , C07C229/08
CPC分类号： C07C227/16 , C07C227/20 , C07C227/32 , C07C229/08
摘要： A process for the preparation of Pregabalin comprising: a) combining an alkali hydroxide and water, b) adding CMH at a temperature of about O° C to about 40° C; c) adding bromine, in a drop-wise manner, at a temperature of about O° C to about 40° C; d) heating; e) reacting with a strong mineral acid; f) extracting with a C4-8 alcohol, and g) mixing with a base to obtain Pregabalin. (Formula I)
-
公开(公告)号：EP1784398A1
公开(公告)日：2007-05-16
申请号：EP05796114.6
申请日：2005-09-02
发明人： HEDVATI, Lilach , PILARSKY, Gideon , RAIZI, Yuriy , MAROM, Esti
IPC分类号： C07D403/10
CPC分类号： C07D405/14
摘要： The present invention provides a process for purifying olmesartan medoxomil.
-
公开(公告)号：EP2545048B1
公开(公告)日：2014-10-08
申请号：EP11714473.3
申请日：2011-04-01
IPC分类号： C07D413/12
CPC分类号： C07D413/12
-
公开(公告)号：EP2545048A1
公开(公告)日：2013-01-16
申请号：EP11714473.3
申请日：2011-04-01
IPC分类号： C07D413/12
CPC分类号： C07D413/12
摘要： The present invention includes new salts of Raltegravir and crystalline forms thereof, pharmaceutical compositions containing the salts or crystalline forms, methods of using the salts or crystalline forms or the compositions to treat HIV infection or to prepare medicament for treating HIV infection, and a process for preparing Raltegravir potassium.
-
公开(公告)号：EP1768950A2
公开(公告)日：2007-04-04
申请号：EP06749819.6
申请日：2006-04-11
IPC分类号： C07C227/32 , C07C229/24 , C07D207/26
CPC分类号： C07D207/277 , C07C227/18 , C07C229/24 , C07D207/08 , C07D207/12 , C07C229/08
摘要： The invention encompasses processes for the synthesis of (S)-Pregabalin, (S)-(+)-3-(aminomethl)-5-methlhexanoic acid.
-
公开(公告)号：EP1716138A1
公开(公告)日：2006-11-02
申请号：EP05793484.6
申请日：2005-09-02
IPC分类号： C07D403/10
CPC分类号： C07D405/14
摘要： The present invention provides a process for preparing olmesartan medoxomil at pH higher than 2.5.
-
7.发明授权
公开(公告)号：EP1879854B1
公开(公告)日：2011-09-07
申请号：EP06759590.0
申请日：2006-05-10
IPC分类号： C07C233/05 , C07C231/20 , C07C215/30 , C07C227/16 , C07C229/08 , A61K31/197 , A61P25/08
CPC分类号： C07C215/30 , C07C227/16 , C07C229/08 , C07C231/20 , C07C233/05
摘要： The invention relates to pure (R)-CMH and to the optical resolution of CMH- racemate, a key intermediate in the synthesis of (S)-Pregabalin. The invention also relates to the process for optically purifying (R)-CMH and to the process for isolatin (S)-CMH from the mother liquor.
-
8.发明公开STEREOSELECTIVE ENZYMATIC SYNTHESIS OF (S) OR (R)-ISO-BUTYL-GLUTARIC ESTER 审中-公开立体选择性酶法合成（S） - 或 （R）-ISO丁基戊二酸
公开(公告)号：EP2297090A1
公开(公告)日：2011-03-23
申请号：EP09770877.0
申请日：2009-06-23
IPC分类号： C07C229/08 , C07C69/42 , C12P41/00
CPC分类号： C07C229/08 , C12P7/62 , C12P41/005
摘要： The present invention relates to a stereoselective enzymatic synthesis of (S) or (R)-iso-butyl-glutaric ester, an intermediate of S-Pregabalin.
-
9.发明公开
公开(公告)号：EP1879854A1
公开(公告)日：2008-01-23
申请号：EP06759590.0
申请日：2006-05-10
IPC分类号： C07C233/05 , C07C231/20 , C07C215/30 , C07C227/16 , C07C229/08 , A61K31/197 , A61P25/08
CPC分类号： C07C215/30 , C07C227/16 , C07C229/08 , C07C231/20 , C07C233/05
摘要： The invention relates to pure (R)-CMH and to the optical resolution of CMH- racemate, a key intermediate in the synthesis of (S)-Pregabalin. The invention also relates to the process for optically purifying (R)-CMH and to the process for isolatin (S)-CMH from the mother liquor.
-
公开(公告)号：EP1866275A1
公开(公告)日：2007-12-19
申请号：EP06749554.9
申请日：2006-04-06
发明人： ARONHIME, Judith , LEVI, Sigalit , HEDVATI, Lilach
IPC分类号： C07C229/08 , A61K31/197 , A61P25/22
CPC分类号： C07C227/42 , C07C229/08
摘要： Crystalline form of Pregabalin characterized by X-ray powder diffraction peaks at about 5.8, 18.4, 19.2, 20.7, and 23.7° 2θ ± 0.2° 2θ, methods for its preparation, its pharmaceutical compositions thereof, and methods for the preparation of crystalline form of Pregabalin characterized by X-ray powder diffraction peaks at about 5.7, 15.4, 17.2, 18.2, and 23.0° 2θ ± 0.2° 2θ, are provided.
摘要翻译： 通过在约5.8,18.4,19.2,20.7和23.7°2θ±0.2°2θ处的X射线粉末衍射峰来表征的普瑞巴林晶体形式，其制备方法，其药物组合物以及制备晶体形式的 提供了特征在于约5.7,15.4,17.2,18.2和23.0°2θ±0.2°2θ处的X射线粉末衍射峰的普瑞巴林。
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.044 秒)
